Low and High HDL Tied to Increased Risk of Mortality

Share this content:
Low and High HDL Tied to Increased Risk of Mortality
Low and High HDL Tied to Increased Risk of Mortality

MONDAY, Oct. 31, 2016 (HealthDay News) -- Low and high levels of high-density lipoprotein (HDL) cholesterol are linked to increased mortality risk, according to a study published in the Nov. 8 issue of the Journal of the American College of Cardiology.

The current findings are based on medical records and other data from 631,762 Ontario adults ages 40 and up. Over five years, 17,952 of them died.

The researchers found that men and women with low HDL levels were more likely to die during the study period, versus those with levels between 40 and 60 mg/dL. But they had increased risks of not only cardiovascular disease death, but also death from cancer or other causes. People with low HDL tended to have lower incomes and higher rates of smoking, diabetes, and hypertension. After the researchers accounted for those factors, low HDL was still linked to higher mortality rates. At the other end of the spectrum, people with very high HDL -- greater than 90 mg/dL -- faced increased risks of dying from non-cardiovascular causes.

"The association of HDL cholesterol levels with conditions that increase the risk of both cardiovascular and non-cardiovascular mortality cast doubt on its role as an independently modifiable risk factor," the authors write. "Future studies should examine specific aspects of HDL cholesterol, such as HDL particle size, subclasses, and function to identify correlates of cardiovascular risk that may be amenable to therapeutic intervention."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »